ClinicalTrials.gg
RecruitingNCT06995898Updated Nov 20, 2026

The Vanguard Study: Testing a New Way to Screen for Cancer

An interventional study of Biospecimen Collection and Device Usage in Bladder Carcinoma, Breast Carcinoma and Colorectal Carcinoma, sponsored by National Cancer Institute (NCI). Recruiting at 49 sites in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 18, 2026Interventions changed5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24,000
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI) — 10 open to participants now, 23 under way, 3 of them phase 3. Urinary Bladder Neoplasms · National Cancer Institute (NCI).

Planned enrollment
Largest of 56
24,000 · median 39
Started
2025
with 3 others
No phase
Only one
of the 67
Primary completion
2029-01
later than 17 of 20 live
Registered
66th of 67
by date

Among the 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI), this one has the largest planned enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2025, is the only one with no phase, reaches primary completion later than 17 of the 20 other live ones, and was the 66th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

10 of the 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI) are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Urinary Bladder Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess the feasibility of recruitment and adherence to protocol-required baseline and follow-up data and blood collection.

II. Assess the feasibility of achieving representative enrollment across participating recruitment sites.

SECONDARY OBJECTIVES:

I. To assess the impact of participant blinding on willingness to participate, adherence to protocol required baseline and follow-up data, blood collection, and rates of standard of care screening.

II. To determine the timeliness of returning test results to participants. III. To understand the factors contributing to lack of diagnostic resolution of an abnormal MCD test.

IV. To examine the effects of participant characteristics, including cancer risk factors and social determinants of health, on all aspects of feasibility.

V. To estimate the proportion of participants receiving an MCD test outside of the trial.

VI. To assess the feasibility of a staggered introduction of the second MCD assay intervention arm.

VII. To estimate the proportion of abnormal MCD tests that are diagnostically resolved, and the time to resolution.

VIII. To compare the proportion of participants who receive standard of care screening during follow-up between the intervention and control arms.

IX. To assess the accuracy of tissue of origin prediction for each MCD assay. X. To estimate the incidence of complications related to diagnostic evaluation of an abnormal MCD test result.

XI. To assess the effect of an abnormal MCD test and diagnostic workup on anxiety and cancer worry.

XII. To evaluate the clinical diagnostic performance of the MCD assays.

EXPLORATORY OBJECTIVES:

I. To estimate rates of late-stage cancer, and the distribution of cancer stage.

II. To estimate assay-targeted cancer-specific mortality of each MCD assay, all cancer-specific mortality, and all-cause mortality.

III. To develop preliminary estimates of the total and incremental budget impact of MCD testing compared to current screening practice from the payor perspective.

IV. To develop preliminary estimates of the economic burden and impact of MCD testing from the participant perspective.

V. To assess the willingness of participants who reported military service to describe military-related environmental exposures by completing the Military Exposure Questionnaire.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM I: Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

ARM II: Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

ARM III (Control): Participants undergo blood collection at enrollment and after one year on study.

After completion of study intervention, participants are followed passively up to 10 years.

03

Conditions studied

  • Bladder Carcinoma
  • Breast Carcinoma
  • Colorectal Carcinoma
  • Esophageal Carcinoma
  • Gastric Carcinoma
  • Liver Carcinoma
  • Lung Carcinoma
  • Malignant Solid Neoplasm
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
  • Prostate Carcinoma
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 45-75 years old
  • Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment
  • Agree to allow collection of information from their medical records for study-related purposes
  • Understand and be able to complete and participant questionnaires in English, Spanish, or Arabic

    • Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion

Exclusion criteria

Exclusion Criteria:

  • Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years

    • Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible. Persons with a history of prostate cancer that has not been treated are not eligible, regardless of when the diagnosis occurred
  • Ongoing cancer diagnostic work-up
  • Ongoing participation in another study of an cancer screening test or technology not currently utilized in routine clinical practice
  • Currently breastfeeding or pregnant, or planning to become pregnant in the next year
  • History of solid organ or hematopoietic transplantation at any time, or blood transfusion within the last 30 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24,000 participants (estimated)

Study arms

  • Experimental
    Arm I (Shield MCD test)

    Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

    Procedure: Biospecimen Collection · Device: Device Usage · Other: Electronic Health Record Review · Procedure: Multi-Cancer Early Detection Test · Other: Questionnaire Administration

  • Experimental
    Arm II (Avantect MCD test)

    Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

    Procedure: Biospecimen Collection · Device: Device Usage · Other: Electronic Health Record Review · Procedure: Multi-Cancer Early Detection Test · Other: Questionnaire Administration

  • Active comparator
    Arm III (Control)

    Participants undergo blood collection at enrollment and after one year on study.

    Procedure: Biospecimen Collection · Other: Electronic Health Record Review · Other: Questionnaire Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • DeviceDevice Usage

    Evaluation of MCD tests

    Also known as: Usage of Device

  • OtherElectronic Health Record Review

    Obtain health data

  • ProcedureMulti-Cancer Early Detection Test

    Undergo Shield MCD test

    Also known as: Early detection (MSED) test, MCD Assay, MCD Test, MCED Assay, MCED Test, MSED Test, Multi Cancer Detection Assay, Multi Cancer Detection Test, Multi Cancer Early Detection Assay, Multi Cancer Early Detection Test, Multi-cancer detection (MCD) test, Multi-Cancer Detection Assay, Multi-Cancer Detection Test, Multi-cancer early detection (MCED) test, Multi-Cancer Early Detection Assay, Multi-cancer screening, Multi-cancer screening test

  • ProcedureMulti-Cancer Early Detection Test

    Undergo Avantect MCD test

    Also known as: Early detection (MSED) test, MCD Assay, MCD Test, MCED Assay, MCED Test, MSED Test, Multi Cancer Detection Assay, Multi Cancer Detection Test, Multi Cancer Early Detection Assay, Multi Cancer Early Detection Test, Multi-cancer detection (MCD) test, Multi-Cancer Detection Assay, Multi-Cancer Detection Test, Multi-cancer early detection (MCED) test, Multi-Cancer Early Detection Assay, Multi-cancer screening, Multi-cancer screening test

  • OtherQuestionnaire Administration

    Study specific questionnaires

06

What researchers measure

Primary outcomes

  1. Feasibility of enrollment onto study

    The number of participants enrolled into the study compared to trial goals.

    Time frame: At time of randomization

  2. Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receipt

    The proportion of participants who are complete questionnaires and timing of completion.

    Time frame: Up to 3 years

  3. Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time point

    The proportion of participants who have a second blood draw and the timing of the blood draw.

    Time frame: Up to 2 years

  4. Proportion of participants considered lost to follow-up within 2 years of randomization

    The proportion of participants who do not complete study procedures and are not able to be contacted.

    Time frame: Up to 2 years

  5. Representative enrollment

    Meeting or exceeding the trial enrollment goals on a population basis.

    Time frame: Up to 2 years

  6. Staggered start of intervention arm 2

    Advantages and challenges arising from trial activation with one intervention arm and later addition of a second intervention arm.

    Time frame: Up to 1 year

Secondary outcomes

  1. Impact of participant blinding

    Comparisons between blinded and unblinded sites on participation rates, adherence to protocol-required questionnaires and blood collection, and participation in standard of care screening.

    Time frame: Up to 2 years

  2. Timely return of MCD test result

    The time from receipt of the MCD test result at the Statistics and Data Management Center to the time of receipt of the MCD test result at the ACCESS Hub. The time from receipt of MCD test result at the ACCESS Hub to the time of participant receipt of the MCD test result.

    Time frame: Up to 2 years

  3. Factors contributing to lack of diagnostic resolution of an abnormal MCD test

    Factors that contribute to the inability to determine if a participant has a cancer or rule out cancer.

    Time frame: Up to 2 years

  4. Contamination

    Estimated as the number of participants receiving MCD testing outside the trial.

    Time frame: Up to 3 years

  5. Effects of participant characteristics

    Feasibility outcomes will be reported by participant demographics and cancer risk factors.

    Time frame: Up to 2 years

  6. Diagnostic resolution following an abnormal MCD test result

    The proportion of participants with a "Cancer diagnosis" or "No cancer diagnosis" among all participants with an abnormal MCD test result will be reported for each MCD test. The fraction of "Unresolved" will also be reported.

    Time frame: Up to 12 years

  7. Time to diagnostic resolution

    Time frame: From date of Hub receipt of abnormal MCD test result to date of provider-reported diagnostic resolution (Cancer diagnosis or No cancer diagnosis), up to 12 months

  8. Participation in standard of care screening

    The proportion of participants that receive standard of care cancer screening in each arm.

    Time frame: Up to 2 years

  9. Accuracy of tissue of origin prediction

    The proportion of diagnosed cancers that match the tissue of origin predicted by an abnormal (positive) MCD test, for each screening episode.

    Time frame: Up to 2 years

  10. Complications related to diagnostic evaluation of an abnormal MCD test result

    Adverse events occurring in participants undergoing a diagnostic workup following receipt of an abnormal MCD test result.

    Time frame: Up to 1 year

  11. Anxiety and Cancer Worry Questionnaire

    Participant anxiety will be assessed with the Patient Reported Outcomes Measurement Information System instrument. Cancer-related worry will be assessed using the Lehrman Cancer Worry Scale.

    Time frame: Up to 2 years

  12. Sensitivity of clinical diagnostic performance of each MCD assay

    Sensitivity will be estimated for each MCD assay. These sensitivities will also be calculated by early- versus late-stage, and for MCD test-targeted cancers and all cancers.

    Time frame: Up to 2 years

  13. Specificity of each MCD assay

    Specificity will be estimated for each MCD assay.

    Time frame: 1 year

  14. Test positive rates

    The proportion of abnormal MCD tests at each screening episode, and the proportion of participants with at least one abnormal test.

    Time frame: Up to 2 years

  15. False positives

    The number of participants with an abnormal MCD test and no cancer diagnosis.

    Time frame: Up to 2 years

  16. (Targeted cancer) Positive predictive value (PPV)

    The proportion of abnormal MCD tests that result in diagnosis of one of the MCD test-targeted cancers among participants with at least one abnormal test, for each screening episode.

    Time frame: Up to 2 years

  17. (All cancer) PPV

    The proportion of abnormal MCD tests that result in diagnosis of any cancer among participants with at least one abnormal test, for each screening episode.

    Time frame: Up to 2 years

  18. Interval cancers

    The number of MCD test-targeted cancer cases diagnosed within 12 months of a normal MCD test result among participants who received an MCD test, for each screening episode.

    Time frame: 1 year

  19. Detected cancers

    The number of cancer cases diagnosed within a 12-month follow-up period of an abnormal test result among participants who received an MCD test, for each screening episode.

    Time frame: 1 year

  20. (Targeted cancer) Negative predictive value

    The proportion of normal MCD tests that did not result in diagnosis of one of the MCD test-targeted cancers among participants with a normal test, for each screening episode.

    Time frame: 1 year

Other outcomes

  1. Cancer stage

    The stage that a cancer was diagnosed (Surveillance, Epidemiology, and End Results \[SEER\]).

    Time frame: Up to 12 years

  2. Early and late stages cancer diagnosis

    Counts of early and late-stage cancers by arm, separately for each cancer type. Early stage is defined as in situ or localized (SEER). Late stage is defined as regional or distant stage (SEER).

    Time frame: Up to 12 years

  3. Targeted cancer-specific mortality of each MCD assay

    The fraction of MCD-targeted cancers diagnosed during trial participation that resulted in death.

    Time frame: Up to 12 years

  4. Cancer-specific mortality

    The fraction of all cancers diagnosed during trial participation that resulted in death.

    Time frame: Up to 12 years

  5. All-cause mortality

    The probability of participant death by any cause during trial participation, by arm.

    Time frame: Up to 12 years

  6. Estimated costs associated with MCD testing minus estimated costs associated with standard of care screening

    Will estimate average screening costs associated with MCD testing.

    Time frame: Up to 12 years

  7. Participant out of pocket costs

    Direct non-medical participant costs; for example, transportation costs, travel time and distance, accommodation costs, childcare or elder-care costs will be elicited through an adapted version of the Costs for Patients Questionnaire. Direct medical care costs paid by participants (e.g., copays, deductible and uncovered medical bills) will be estimated using Medicare reimbursement and coinsurance rates for services received (Medicare Parts A-D).

    Time frame: Up to 2 years

  8. Participant work loss

    Participant and caregiver time spent away from work will be estimated using an adapted version of the Productivity Cost Questionnaire. The dollar value of hours recorded for participant work loss and caregiver time will be estimated using wages from the Bureau of Labor Statistics.

    Time frame: Up to 2 years

  9. Proportion of participants who complete the Military Exposure Questionnaire

    Will evaluate the proportion of participants who complete the Military Exposure Questionnaire, among those who reported military service.

    Time frame: At baseline

07

Study locations

49 of 49 sites recruiting
  • Kaiser Permanente-Division of Research
    Pleasanton, California 94588, United States
    Recruiting
    • Site Public Contact · Contact510-891-3400
    • Jeffrey Lee · Principal investigator
  • Naval Medical Center -San Diego
    San Diego, California 92134, United States
    Recruiting
    • Site Public Contact · Contact619-532-8712
    • Brittany E. Powell · Principal investigator
  • Keefe Memorial Hospital
    Cheyenne Wells, Colorado 80810, United States
    Recruiting
    • Site Public Contact · Contactcmillsap@keefemh.org · 719-767-5661
    • Linda S. Cook · Principal investigator
  • Kaiser Permanente-Franklin
    Denver, Colorado 80205, United States
    Recruiting
    • Site Public Contact · ContactKPCOIHRClinicalResearch@kp.org · 303-817-9295
    • Debra P. Ritzwoller · Principal investigator
    • Larissa L. White · Principal investigator
  • Poudre Valley Hospital
    Fort Collins, Colorado 80524, United States
    Recruiting
    • Site Public Contact · Contact970-297-6150
    • Linda S. Cook · Principal investigator
  • Cancer Care and Hematology-Fort Collins
    Fort Collins, Colorado 80528, United States
    Recruiting
    • Site Public Contact · Contactctsucontact@westat.com · 888-823-5923
    • Linda S. Cook · Principal investigator
  • UCHealth Greeley Hospital
    Greeley, Colorado 80631, United States
    Recruiting
    • Site Public Contact · Contactctsucontact@westat.com · 888-823-5923
    • Linda S. Cook · Principal investigator
  • Kaiser Permanente-Rock Creek
    Lafayette, Colorado 80026, United States
    Recruiting
    • Site Public Contact · ContactKPCOIHRClinicalResearch@kp.org · 303-817-9295
    • Debra P. Ritzwoller · Principal investigator
    • Larissa L. White · Principal investigator
  • Kaiser Permanente-Lone Tree
    Lone Tree, Colorado 80124, United States
    Recruiting
    • Site Public Contact · ContactKPCOIHRClinicalResearch@kp.org · 303-817-9295
    • Debra P. Ritzwoller · Principal investigator
    • Larissa L. White · Principal investigator
  • Medical Center of the Rockies
    Loveland, Colorado 80538, United States
    Recruiting
    • Site Public Contact · Contact970-203-7083
    • Linda S. Cook · Principal investigator
  • Kaiser Permanente Moanalua Medical Center
    Honolulu, Hawaii 96819, United States
    Recruiting
    • Site Public Contact · Contactshelley.a.clark@kp.org · 808-432-5195
    • Stacey Honda · Principal investigator
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889-5600, United States
    Recruiting
    • Site Public Contact · Contact301-319-2100
    • Kristen Natale · Principal investigator
  • Henry Ford Cancer Institute-Downriver
    Brownstown, Michigan 48183, United States
    Recruiting
    • Site Public Contact · ContactCTOResearch@hfhs.org · 313-916-3721
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Health Center - Brownstown
    Brownstown, Michigan 48183, United States
    Recruiting
    • Site Public Contact · ContactCDUDAS1@hfhs.org · 313-874-5472
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Health Center - Chesterfield
    Chesterfield, Michigan 48047, United States
    Recruiting
    • Site Public Contact · ContactCDUDAS1@hfhs.org · 313-874-5472
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Macomb Hospital-Clinton Township
    Clinton Township, Michigan 48038, United States
    Recruiting
    • Site Public Contact · ContactCTOResearch@hfhs.org · 313-916-3721
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center-Fairlane
    Dearborn, Michigan 48126, United States
    Recruiting
    • Site Public Contact · ContactCTOResearch@hfhs.org · 313-916-3721
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Recruiting
    • Site Public Contact · ContactCTOResearch@hfhs.org · 313-916-3721
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center - Detroit Northwest
    Detroit, Michigan 48235, United States
    Recruiting
    • Site Public Contact · Contactkkeenan1@hfhs.org
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center-Cottage
    Grosse Pointe Farms, Michigan 48236, United States
    Recruiting
    • Site Public Contact · Contact313-916-1784
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center - Livonia
    Livonia, Michigan 48150, United States
    Recruiting
    • Site Public Contact · Contactkkeenan1@hfhs.org
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center-Columbus
    Novi, Michigan 48377, United States
    Recruiting
    • Site Public Contact · ContactCTOResearch@hfhs.org · 313-916-3721
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center - Plymouth
    Plymouth, Michigan 48170, United States
    Recruiting
    • Site Public Contact · Contactkkeenan1@hfhs.org
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center - Royal Oak
    Royal Oak, Michigan 48067, United States
    Recruiting
    • Site Public Contact · Contactkkeenan1@hfhs.org
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center
    Sterling Heights, Michigan 48310, United States
    Recruiting
    • Site Public Contact · Contactctsucontact@westat.com · 888-823-5923
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Medical Center - Troy
    Troy, Michigan 48083, United States
    Recruiting
    • Site Public Contact · Contactkkeenan1@hfhs.org
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford West Bloomfield Hospital
    West Bloomfield, Michigan 48322, United States
    Recruiting
    • Site Public Contact · ContactCTOResearch@hfhs.org · 313-916-3721
    • Christine Neslund-Dudas · Principal investigator
  • Henry Ford Wyandotte Hospital
    Wyandotte, Michigan 48192, United States
    Recruiting
    • Site Public Contact · Contactnhay@hfhs.org
    • Christine Neslund-Dudas · Principal investigator
  • Minneapolis VA Medical Center
    Minneapolis, Minnesota 55417, United States
    Recruiting
    • Site Public Contact · Contact612-467-2800
    • Mark A. Klein · Principal investigator
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
    Recruiting
    • Site Public Contact · Contactaroland@kccop.org · 913-948-5588
    • Timothy J. Pluard · Principal investigator
  • Kansas City Veterans Affairs Medical Center
    Kansas City, Missouri 64128, United States
    Recruiting
    • Site Public Contact · Contact800-525-1483
    • Suman Kambhampati · Principal investigator
  • CoxHealth South Hospital
    Springfield, Missouri 65807, United States
    Recruiting
    • Site Public Contact · Contact417-269-4520
    • Aimee S. James · Principal investigator
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Site Public Contact · Contactinfo@siteman.wustl.edu · 800-600-3606
    • Aimee S. James · Principal investigator
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • Durham VA Medical Center
    Durham, North Carolina 27705, United States
    Recruiting
  • Louis Stokes Cleveland VA Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Site Public Contact · Contactholly.henry@va.gov
    • Charles J. Nock · Principal investigator
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Audie L Murphy VA Hospital
    San Antonio, Texas 78229, United States
    Recruiting
    • Site Public Contact · Contact877-469-5300
  • Sentara Martha Jefferson Hospital
    Charlottesville, Virginia 22911, United States
    Recruiting
    • Site Public Contact · Contact434-654-8400
    • John M. Sayles · Principal investigator
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
    Recruiting
  • Inova Fair Oaks Hospital
    Fairfax, Virginia 22033, United States
    Recruiting
  • Sentara Rockingham Memorial Hospital Hahn Cancer Center
    Harrisonburg, Virginia 22801, United States
    Recruiting
    • Site Public Contact · Contact540-689-7000
    • John M. Sayles · Principal investigator
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
    Recruiting
    • Site Public Contact · Contact757-388-2406
    • John M. Sayles · Principal investigator
  • Naval Medical Center - Portsmouth
    Portsmouth, Virginia 23708-2197, United States
    Recruiting
    • Site Public Contact · Contact757-953-5939
    • John C. Mattingly · Principal investigator
  • VCU Massey Cancer Center at Stony Point
    Richmond, Virginia 23235, United States
    Recruiting
    • Site Public Contact · Contactctoclinops@vcu.edu
    • Alexander H. Krist · Principal investigator
  • VCU Massey Comprehensive Cancer Center
    Richmond, Virginia 23298, United States
    Recruiting
    • Site Public Contact · ContactCTOclinops@vcu.edu · 804-628-6430
    • Alexander H. Krist · Principal investigator
  • VCU Community Memorial Health Center
    South Hill, Virginia 23970, United States
    Recruiting
  • Madigan Army Medical Center
    Tacoma, Washington 98431, United States
    Recruiting
  • Zablocki Veterans Administration Medical Center
    Milwaukee, Wisconsin 53295, United States
    Recruiting
    • Site Public Contact · Contact888-469-6614
    • Jeffrey C. Whittle · Principal investigator
08

References and documents

Publications

  • Guthrie KA, Anderson GL, Bell-Brown A, Cook LS, Doescher MP, Etzioni RB, Feng Z, Henderson LM, Herman J, Honda SA, James AS, Kaltman R, Kooperberg C, Krist AH, Lee CB, Lee JK, LeeVan E, Liao JC, Minasian LM, Moore KN, Nana-Sinkam P, Natale KE, Neslund-Dudas C, Ngo-Metzger Q, Ong MJC, Oshiro CES, Park Y, Patriotis C, Pinsky P, Prorok PC, Reuland DS, Ritzwoller DP, Rubinstein WS, Sakoda LC, Sayles J, Schenk JM, Shofer S, Simoff M, Toriola AT, White L, Wion ES, Wood M, Ramsey SD. The vanguard study: Assessing feasibility of conducting randomized trials of novel multi-cancer detection tests. Contemp Clin Trials. 2026 Aug 9:108418. doi: 10.1016/j.cct.2026.108418. Online ahead of print. PubMed 42571808 ↗

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2029, 43 months after the start.

Of 237 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's planned 43 months is close to that.

Counting every sponsor, half of 246 studies reached it within 38 months; a quarter within 18 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2025
First posted
May 30, 2025
StartActual
Jun 18, 2025
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jun 30, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (5 United States)
  • CoxHealth South Hospital · Springfield, United States
  • Naval Medical Center -San Diego · San Diego, United States
  • Kansas City Veterans Affairs Medical Center · Kansas City, United States
  • Audie L Murphy VA Hospital · San Antonio, United States
  • Sentara Rockingham Memorial Hospital Hahn Cancer Center · Harrisonburg, United States
across 3 updates, Oct 6, 2026 – Nov 18, 2026
Interventions
Changed Multi-Cancer Detection Test→Multi-Cancer Early Detection Test; Multi-Cancer Detection Test→Multi-Cancer Early Detection Test
Nov 4, 2026
Secondary outcomes
Revised in 2 updates
What changed on Nov 4, 2026
  • Time frameDiagnostic resolution following an abnormal MCD test resultWithin 12 months following an abnormal MCD test result → From initial diagnostic workup result to final diagnostic workup result (within 12 months of the abnormal MCD test result)
  • Time frameTime to diagnostic resolutionUp to 2 years → From date of Hub receipt of abnormal MCD test result to date of provider-reported diagnostic resolution (Cancer diagnosis or No cancer diagnosis), up to 12 months
  • DescriptionDiagnostic resolution following an abnormal MCD test result: how it is measured was reworded
  • DescriptionTime to diagnostic resolution: how it is measured was reworded
  • Descriptionother outcomeParticipant out of pocket costs: how it is measured was reworded
What changed on Nov 6, 2026
  • Time frameDiagnostic resolution following an abnormal MCD test resultFrom initial diagnostic workup result to final diagnostic workup result (within 12 months of the abnormal MCD test result) → Up to 12 years
  • Descriptionother outcomeEstimated costs associated with MCD testing minus estimated costs associated with standard of care screening: how it is measured was reworded
across 2 updates, Nov 4, 2026 – Nov 6, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Walter Reed National Military Medical Center · Bethesda, United StatesContact •••9823→•••2100
  • Kaiser Permanente-Franklin · Denver, United StatesContact added (no phone or email listed)
  • Kaiser Permanente-Rock Creek · Lafayette, United StatesContact added (no phone or email listed)
  • Kaiser Permanente-Lone Tree · Lone Tree, United StatesContact added (no phone or email listed)
across 3 updates, Oct 5, 2026 – Nov 20, 2026
Show all 6 updates
  1. Nov 20, 2026
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Kaiser Permanente-Franklin · Denver, United StatesContact added (no phone or email listed)
    • Kaiser Permanente-Rock Creek · Lafayette, United StatesContact added (no phone or email listed)
    • Kaiser Permanente-Lone Tree · Lone Tree, United StatesContact added (no phone or email listed)
  2. Nov 18, 2026
    3 sites added
    Show 3 added (3 United States)
    • Kansas City Veterans Affairs Medical Center · Kansas City, United States
    • Audie L Murphy VA Hospital · San Antonio, United States
    • Sentara Rockingham Memorial Hospital Hahn Cancer Center · Harrisonburg, United States
    + 1 other change: verification date
  3. Nov 6, 2026
    1 site added
    Show site
    • Naval Medical Center -San Diego · San Diego, United States
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameDiagnostic resolution following an abnormal MCD test resultFrom initial diagnostic workup result to final diagnostic workup result (within 12 months of the abnormal MCD test result) → Up to 12 years
    • Descriptionother outcomeEstimated costs associated with MCD testing minus estimated costs associated with standard of care screening: how it is measured was reworded
  4. Nov 4, 2026
    Secondary outcomes 2 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameDiagnostic resolution following an abnormal MCD test resultWithin 12 months following an abnormal MCD test result → From initial diagnostic workup result to final diagnostic workup result (within 12 months of the abnormal MCD test result)
    • Time frameTime to diagnostic resolutionUp to 2 years → From date of Hub receipt of abnormal MCD test result to date of provider-reported diagnostic resolution (Cancer diagnosis or No cancer diagnosis), up to 12 months
    • DescriptionDiagnostic resolution following an abnormal MCD test result: how it is measured was reworded
    • DescriptionTime to diagnostic resolution: how it is measured was reworded
    • Descriptionother outcomeParticipant out of pocket costs: how it is measured was reworded
    Interventions Changed Multi-Cancer Detection Test→Multi-Cancer Early Detection Test; Multi-Cancer Detection Test→Multi-Cancer Early Detection Test
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Walter Reed National Military Medical Center · Bethesda, United StatesContact •••9823→•••2100
  5. Oct 6, 2026
    1 site added
    Show site
    • CoxHealth South Hospital · Springfield, United States
  6. Oct 5, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Walter Reed National Military Medical Center · Bethesda, United StatesContact •••2100→•••9823

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06995898
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Jun 18, 2025
Primary completion
Jan 31, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Scott D Ramsey
principal investigator · Fred Hutchinson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion